Changes in serum sphingomyelin after Roux-en-Y gastric bypass surgery are related to diabetes status by Carlsson, Elin Rebecka et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Changes in serum sphingomyelin after Roux-en-Y gastric bypass surgery are related
to diabetes status
Carlsson, Elin Rebecka; Grundtvig, Josefine Liv Gilling; Madsbad, Sten; Fenger, Mogens
Published in:
Frontiers in Endocrinology
DOI:
10.3389/fendo.2018.00172
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Carlsson, E. R., Grundtvig, J. L. G., Madsbad, S., & Fenger, M. (2018). Changes in serum sphingomyelin after
Roux-en-Y gastric bypass surgery are related to diabetes status. Frontiers in Endocrinology, 9(APR), [172].
https://doi.org/10.3389/fendo.2018.00172
Download date: 03. Feb. 2020
April 2018 | Volume 9 | Article 1721
Original research
published: 25 April 2018
doi: 10.3389/fendo.2018.00172
Frontiers in Endocrinology | www.frontiersin.org
Edited by: 
Åke Sjöholm, 
Gävle Hospital, Sweden
Reviewed by: 
Akinobu Nakamura, 
Hokkaido University, Japan  
Dilek Gogas Yavuz, 
Marmara University, Turkey
*Correspondence:
Elin Rebecka Carlsson 
elin.rebecka.carlsson@regionh.dk
Specialty section: 
This article was submitted 
to Diabetes, 
a section of the journal 
Frontiers in Endocrinology
Received: 08 December 2017
Accepted: 03 April 2018
Published: 25 April 2018
Citation: 
Carlsson ER, Grundtvig JLG, 
Madsbad S and Fenger M (2018) 
Changes in Serum Sphingomyelin 
After Roux-en-Y Gastric 
Bypass Surgery Are 
Related to Diabetes Status. 
Front. Endocrinol. 9:172. 
doi: 10.3389/fendo.2018.00172
changes in serum sphingomyelin 
after roux-en-Y gastric Bypass 
surgery are related to Diabetes 
status
Elin Rebecka Carlsson1*, Josefine Liv Gilling Grundtvig2, Sten Madsbad2 and  
Mogens Fenger1
1 Department of Clinical Biochemistry, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark, 2 Department of 
Endocrinology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark
Metabolic surgery is superior to lifestyle intervention in reducing weight and lowering 
glycemia and recently suggested as treatment for type 2 diabetes mellitus. Especially 
Roux-en-Y gastric bypass (RYGB) has been focus for much research, but still the mecha-
nisms of action are only partly elucidated. We suggest that several mechanisms might be 
mediated by sphingolipids like sphingomyelin. We measured serum sphingomyelin before 
and up to 2 years after RYGB surgery in 220 patients, divided before surgery in one non- 
diabetic subgroup and two diabetic subgroups, one of which contained patients obtaining 
remission of type 2 diabetes after RYGB, while patients in the other still had diabetes after 
RYGB. Pre- and postoperative sphingomyelin levels were compared within and between 
groups. Sphingomyelin levels were lower in diabetic patients than in non-diabetic patients 
before surgery. Following RYGB, mean sphingomyelin concentration fell significantly in the 
non-diabetic subgroup and the preoperative difference between patients with and with-
out diabetes disappeared. Changes in diabetic subgroups were not significant. Relative 
to bodyweight, an increase in sphingomyelin was seen in all subgroups, irrespective 
of diabetes status. We conclude that RYGB has a strong influence on sphingomyelin 
metabolism, as seen reflected in changed serum levels. Most significantly, no differences 
between the two diabetic subgroups were detected after surgery, which might suggest 
that patients in both groups still are in a “diabetic state” using the non-diabetic subgroup 
as a reference.
Keywords: sphingolipids, diabetes, obesity, gastric bypass surgery, metabolic surgery, sphingomyelin, human, 
clinical research
inTrODUcTiOn
Several studies have shown that operations, where a part of the proximal intestine is isolated from 
ingested food, can treat type 2 diabetes mellitus independent of weight loss (1, 2). The Roux-en-Y 
gastric bypass (RYGB) procedure has been of special interest since remission of diabetes is often 
reported shortly after surgery before any significant weight loss, but also because of the major weight 
loss of about 40 kg the first year after surgery (3). It has been suggested that one of RYGB’s major effects 
on glucose hemostasis is mediated through an enhanced increase of glucagon-like peptide-1 (GLP-1) 
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during a meal and an improvement of hepatic insulin sensitiv-
ity already few days after surgery. Later, following the weight loss 
also insulin sensitivity in the skeletal muscles is improved (4, 5). 
Nevertheless, the mechanisms underlying the glycemic effects of 
RYGB surgery are not fully elucidated and still debated (6).
A link between lipid metabolism and inflammation has 
been suggested to mediate metabolic disease (7). Key players 
in this signaling network seem to be sphingolipids (8–10), a 
large family of lipids with important roles in membrane biol-
ogy and cellular signaling (11), and there is strong evidence 
for sphingolipids to be involved in development of insulin 
resistance (10, 12, 13). Ceramide, is suggested to play a signifi-
cant role in inducing β-cell apoptosis, as well as in mediating 
insulin resistance and reducing insulin gene expression (14); 
sphingosine-1-phosphate, has been shown to improve β-cell 
function, promote glucose-stimulated insulin release, and 
protect against β-cell apoptosis (15); and sphingomyelin, which 
will be described more in details below has been connected to 
insulin resistance in animal studies (16, 17).
So far, a limited number of studies have connected metabolic 
surgery and sphingolipids, looking at changes in sphingolipids 
after mainly RYGB (18–23). Apart from the study by Kayser, they 
all include a quite small number of patients. The conclusions from 
these studies are that sphingolipid metabolism changes after RYGB 
(18–23), that the changes are associated with diabetes remission 
(22), and that similar changes are not seen after adjustable gastric 
banding (AGB) (21).
Among the sphingolipids, sphingomyelin is the most abundant 
(16, 24). It consists of a phosphocholine head group on a body 
of ceramide (11, 16, 25) and is either synthesized by sphingomy-
elin synthase from ceramide and phosphocholine or cleaved by 
sphingomyelinase to cera mide (25–27). Modulation of sphingo-
myelin content in cellular membranes seem to influence insulin 
sensitivity in mice models (28), indeed sphingomyelin seem to 
have important roles in regulating membrane structure, cellular 
signaling, -migration, and nuclear function (26).
Of the clinical studies mentioned earlier, only the latest three 
lipidomic studies include measurements of sphingomyelin, spe-
cifically (21–23). Graesslers study of five morbidly obese patients, 
four of which had type 2 diabetes, found no significant change in 
total plasma sphingomyelin, but 7 out of 22 sphingomyelin spe-
cies, that differ in their content of fatty acids, were significantly 
reduced 3 months after RYGB, compared to baseline (23). Arora 
found a negative correlation between some sphingomyelin species 
and insulin levels 4 days after RYGB in 16 insulin-resistant sub-
jects, where 14 had type 2 diabetes. Sphingomyelin species were 
also among the variables that were most discriminatory between 
time points and at their lowest level 42 days after RYGB (22). In a 
cohort of 59 obese women, Kayser compared serum lipid profiles 
at baseline and after either RYGB or AGB. At 1 and 3  months 
after surgery, respectively, there were 21 and 19 patients left in 
the RYGB-group. After surgery, 12 patients were left in the AGB-
group. In this study, several lipids were differentially affected by 
the two types of surgery, some of them species of sphingomyelin. 
Interestingly, monounsaturated sphingomyelin species decreased 
after RYGB, whereas polyunsaturated sphingomyelin species 
increased (21).
In this study, we look at sphingomyelin in serum before and 
after RYGB surgery in a large patient cohort (n  =  220). We 
hypothesized that sphingomyelin levels change after RYGB and 
that changes are related to glucose tolerance and weight loss.
research Design anD MeThODs
research Population and Biobank
We have previously described the research population of patients 
treated for obesity between 2009 and 2014 at Hvidovre University 
Hospital in the Capital Region of Copenhagen (29). From this 
population, we selected all RYGB-operated patients operated 
between November 2010 and September 2013, who had delivered 
a fasting serum blood sample before their operation and, since 
we were especially interested in early changes after RYGB, also 
had delivered a fasting sample within 4 months after their opera-
tion. We then included all fasting serum blood samples from the 
same patients up to 2 years after surgery, ending up with a total 
of 835 samples from 220 patients. Of these samples, 220 were 
from prior to surgery, and 220, 158, 148, and 89 were from 3, 
6, 12, and 24 months after surgery, respectively. Serum samples 
had all been frozen shortly after sampling at −80°C and stored 
between 6 months and 5 years at the time for our sphingomyelin 
analysis. Clinical characteristics as weight and BMI, systolic 
and diastolic blood pressure were for a majority of the patients 
registered in a database at several time points during the course 
of treatment. We also had access to biochemical laboratory data 
from 2009 and onward. The surgical technique and methods 
for biochemical analyses are described in the above mentioned 
paper (29). This study was performed in accordance with the 
Helsinki Declaration and was approved by the Scientific Ethics 
Committee of the Capital Region, Denmark, protocol number 
HD2009-78, extended with the protocol number H-6-2014-029, 
and by the Danish Data Protection Agency. Informed consent 
was obtained in writing from all the participants in this study.
sphingomyelin assay Principle
The samples were analyzed in double with an in-house sphingo-
myelin assay, all samples from the same patient in sequence at the 
same time of analyzing.
The method was modified from other similar, previously 
described methods (30, 31), determining the concentration of 
sphingomyelin by measuring free choline in a 10-µL serum sample 
after incubation with sphingomyelinase (0.05 U), alkaline phos-
phatase (5 U), choline oxidase (0.35 U), and peroxidase (15 U) 
in 100 µL of a buffer of 0.05 M Trishydrochlorid and 0.66 mM 
Calcium Chloride buffer (pH 8) with 0.05% Triton X-100, 
added 2 mM DAOS [N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-
dimethox-yaniline] and 0.72  mM 4-aminoantipyrin. Instead 
of using a standard of sphingomyelin-extract from a biological 
source, we chose to use a standard solution of choline chloride 
(10,000  µmol/L diluted with buffer to concentrations between 
250 and 750  µmol/L) and used sphingomyelin (diluted in 2% 
triton X-100 in ethanol) for assay level control. Reagents were 
choline oxidase (037-14401) from Wako Chemicals GmbH and 
(C4405) from Sigma-Aldrich; sphingomye linase (S8633), alkaline 
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phosphatase (P6774), peroxidase (P6782), 4-aminoantipyrine 
(A4382), DAOS (E8381), sphingomyelin (S0756), choline chlo-
ride (C7017), and Triton X-100 from Sigma-Aldrich Denmark 
A/S; sphingomyelin (860061  C) from Avanti Polar Lipids, Inc.; 
Ultrapure™, Trishydrochlorid, and ethanol from Merck & Co., 
Inc.; and calcium chloride from Invitrogen (Thermo Fisher 
Scientific).
End point absorbances at 595  nm were read spectrophoto-
metrically after 60 min in 37°C by SpectraMax i3x from Molecular 
Devices on a standard 96-well microplate. Results were calculated 
with the software SoftMax Pro 6.4 and could be reproduced in 
double within the same run with a SD 5.6 µmol/L and a CV at 
1.3%. Intermediary precision SD was 7.9 µmol/L and the CV 1.6% 
at the level of 495 µmol/L over five independent time points of 
analysis. Linearity was documented by serial dilution of a sample 
with high concentration from 82 to 582  µmol/L and recovery 
when adding sphingomyelin of known concentration to a sample 
with an endogenous sphingomyelin concentration at 365 µmol/L 
was between 101 and 106%. We also checked for possible interfer-
ence by phosphatidylcholine, by adding known concentrations of 
phosphatidylcholine to a sample. This did not raise the measured 
concentration of sphingomyelin.
Apart from serum, heparin plasma can also be used in this 
assay, but not plasma treated with EDTA or citrate. No lipid 
extraction is necessary.
As endogenous free choline and possibly free hydrogen 
peroxide can interfere, we repeated the analysis with a lower set 
of standards and without sphingomyelinase and alkaline phos-
phatase and then adjusted the result from the sphingomyelin 
measurement. This part of the assay had SD 1.7 µmol/L and CV 
of 5.3% for within run double determinations and the intermediary 
precision SD 2.2 µmol/L and CV of 5.8%.
Definition of remission and subdivision 
into subgroups according to Diabetes 
status
Based on the cutoff limits in WHO’s diagnostic criteria for diabetes 
mellitus (DM), patients were assumed to have DM only if avail-
able lab data could confirm measure of HbA1c at 6.5% (48 mmol/
mol) or above, fasting glucose at 7 mmol/L or above, or glucose 
at 2-h of a glucose tolerance test at 11.1 mmol/L or above. We 
used the criteria for remission suggested by American Diabetes 
Association (ADA) in 2009 (32), but without distinguishing 
between partial, complete, or prolonged remission. In practice, a 
patient was said to be in remission after RYGB if HbA1c decreased 
to below 6.5% (48 mmol/mol) without any antidiabetic medica-
tion and then stayed low for as long as there were available clinical 
data, varying from 2 years to a maximum of 5 years.
We divided the 220 patients into five different subgroups: 
NDM, a non-DM group (n = 151); DMH-NDM, a group with 
DM and hyperglycemia in remission after RYGB (n = 34); DMH-
DMH, a group with DM and hyperglycemia not in remission after 
RYGB (n = 20); DMT-NDM, a heterogeneous group with possible 
DM and in treatment with diet or antidiabetic medication before 
RYGB, but with no confirmed hyperglycemia in lab data and off 
antidiabetic treatment after RYGB (n =  14); DMH-DMT, one 
patient with DM and hyperglycemia before RYGB in biochemical 
remission but still on antidiabetic treatment after RYGB (n = 1). 
Only the first three subgroups were compared in statistical analy-
ses and further discussed in this paper.
reference Population
To establish a reference interval, we picked 238 samples from a 
biobank with samples from a healthy normal weight population. 
Samples had all been stored for about 15 years at −80°C, thawed 
and refrozen a few but equal times.
adjustment of hba1c levels Before 
January 2013
Scandinavian laboratories that are using high pressure liquid 
chromatographic (HPLC) methods for determining HbA1c were 
until January 2013 measuring higher levels compared to the rest 
of Europe (33). This systematical bias was eventually found to 
be due to the used calibrator, which was then substituted with 
another, resulting in lower levels than previously, but in agree-
ment with international reference levels. When comparing 
HbA1c levels measured with HPLC that spread over time on 
both sides of this calibrator change, we have followed recom-
mendations and adjusted levels analyzed before January 2013 
with −2.7 mmol/mol.
statistical analysis
Overall, data are expressed as mean with a 95% confidence interval 
or SD. Correlations are shown as Pearson or Spearman correlation 
coefficients r or rs, with the degree of freedom and p-value. We 
have used IBM SPSS version 22 for all analysis.
As most of the parameters are normally distributed and with 
homogeneity of variances, we have used parametric tests like 
the one-way ANOVA and Tukey post hoc test for our multiple 
comparisons between groups, the independent t-test for com-
paring only two subgroups and a paired t-test for comparing 
the same group of patients before and after RYGB. In situations 
where Levene’s test of equality of variances was significant, we 
performed the one-way ANOVA with a Welch–Satterthwaite 
correction followed by a Games–Howell post hoc test. If there 
were outliers that were considered extreme when assessed by 
inspection of a boxplot (and this was not due to any analytical 
error) we performed statistical analysis both with and without 
the outliers in the data material. Generally, removing the outli-
ers did not change but rather increased significance. In order 
not to overestimate significance, we have, therefore, chosen to 
report the more conservative p-values from analysis with all 
possible outliers in the material. Only a few of our parameters, 
like for instance HbA1c and triglycerides did not have a normal 
distribution. Where this was the case, and differences between 
subgroups were statistically significant using the normal one-
way ANOVA, we confirmed the statistical significance with a 
Kruskal–Wallis H-test. Linear relationships between lipids were 
determined by Spearman’s correlation. Linear relationships 
between sphingomyelin and weight were determined by the 
Pearson correlation. p-Values lower than 0.05 were considered 
significant.
TaBle 1 | Preoperative clinical characteristics and sphingomyelin (SM) concentration for all patients and patients grouped according to diabetes status, alongside a 
normal weight reference population.
all patients 
(n = 220)a
nDM  
(n = 151)
DMh-nDM  
(n = 34)
DMh-DMh  
(n = 20)
anOVa  
p-value†
reference  
(n = 238)
t-Test  
p-value‡
Mean (sD) Mean (sD) Mean (sD) Mean (sD) Mean (sD)
Age (years) 44.6 (9.5) 42.1 (9.0) 50.5 (8.1)* 51.5 (7.4)* 7 e−9 45.5 (8.9)* 2 e−4
Gender (f/m) 150/70 113/38 18/16 9/11 ND 121/119 ND
Height (cm) 171.8 (9.6) 171.0 (9.8) 174.5 (8.0) 171.2 (11.4) 0.167 171.1 (9.3) 0.946
Weight (kg) 125.2 (21.6) 126.3 (22.4) 126.4 (20.6) 117.6 (19.7) 0.244 79.3 (15.4)* 2 e−61
BMI (kg/m2) 42.3 (5.8) 43.1 (5.9) 41.4 (5.4) 40.0 (3.6)* 0.006 27.0 (4.5)* 2 e−81
Systolic BP (mmHg) 128 (14.7) 126.8 (14.9) 131.2 (12.6) 128.2 (14.7) 0.285 132.1 (19.2)* 0.004
Diastolic BP (mmHg) 82.2 (10.1) 82.0 (11.0) 81.4 (6.8) 82.4 (10.1) 0.93 82.3 (16.7) 0.829
HbA1c (mmol/mol) 39.0 (9.7) 34.5 (3.8) 48.8 (11.7)* 55.2 (10.0)* 4 e−12 40.6 (5.8)* 6 e−26
HbA1c (%) 5.7 (0.89) 5.3 (0.35) 6.6 (1.07) 6.9 (0.91) ND 5.9 (0.53) ND
Cholesterol (mmol/L)
Total- 4.74 (1.04) 4.98 (0.96) 4.22 (1.11)* 4.24 (1.17)* 4 e−5 5.52 (1.08)* 8 e−7
HDL- 1.15 (0.30) 1.19 (0.29) 1.06 (0.36) 1.09 (0.35) 0.038 1.35 (0.32)* 2 e−6
LDL- 2.88 (0.95) 3.12 (0.85) (n = 32)
2.36 (0.97)*
(n = 18)
2.27 (1.13)*
1 e−6 (n = 68)
3.69 (0.97)*
2 e−5
VLDL- 0.71 (0.32) 0.67 (0.30) (n = 32)
0.75 (0.30) 
(n = 18)
0.89 (0.47)
0.086 (n = 68)
0.58 (0.25)*
0.033
Triglycerides (mmol/L) 1.67 (1.09) 1.50 (0.74) 2.11 (1.95) 2.13 (1.26) 0.038 1.27 (0.83)* 0.006
SM (μmol/L) 413.1 (93.2) 437.2 (84.0) 360.3 (101.2)* 343.2 (84.0)* 4.5 e−8 416.70 (111.4)# 0.04
Female patients 434.3 (90.3) 449.1 (83.7) 384.9 (105.6)* 381.6 (105.0) 0.003 460.8 (94.5) 0.32
Male patients 367.6 (83.0) 401.7 (75.3) 332.6 (91.4)* 311.7 (46.6)* 0.001 371.1 (109.4) 0.11
Data are reported as mean (SD). If the number of patients with available clinical data was less than 95% of the total of patients in the group, the actual number is specified. Age is 
on the day of surgery. Clinical data represent the closest available before surgery. NDM, patients without diabetes mellitus (DM); DMH-NDM, patients with DM in remission after 
Roux-en-Y gastric bypass surgery (RYGB); DMH-DMH, patients with DM not in remission after RYGB; Reference, a population of healthy individuals with normal weight; ND, not 
determined; SM, sphingomyelin concentrations are shown for all, followed by concentrations for female and male patients, respectively.
aAll patients also include 15 patients who belong to other subgroups than the three showed in table.
†p-Value from ANOVA comparing the three patient subgroup means.
‡p-Value from independent samples t-test comparing the reference group mean to the mean in the patient subgroup NDM.
*Indicates significant difference (p < 0.05) when compared to the NDM group. No significant difference was found between the two diabetes subgroups. The two diabetes 
subgroups were not compared to the reference group.
#SM concentration in serum is higher in women than in men (p = 3.9 e−7). This explains the low p-value in the comparison of reference population and NDM group, as the gender 
distribution is different in the two groups. Post hoc p-values from Tukey and Games–Howell are not shown in table.
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As weight and BMI in this population were not stationary 
after RYGB, and because this change in mass and volume possibly 
could have different influence on different parameters, we chose 
to standardize lipid concentration to bodyweight or BMI in some 
statistical analyses.
resUlTs
Of our 220 patients, 151 (NDM) did not have DM and 54 had 
DM that we were able to confirm in biochemical laboratory data. 
Of the patients with diabetes, 34 (DMH-NDM) were able to con-
trol glucose levels at HbA1c < 6.5% (48 mmol/mol) after RYGB 
without antidiabetic medication, but 20 (DMH-DMH) still had 
high HbA1c values after RYGB. As described in the Section 
“Research Design and Methods,” 15 patients were not in any of 
these three groups.
The serum samples were drawn 4.54 (4.10–4.99) months prior 
to surgery, followed up by serum samples at 3.07 (3.03–3.12), 
6.44 (6.26–6.63), 12.39 (12.12–12.66), and 24.23 (23.73–24.74) 
months after surgery. Total-, HDL-, LDL- and VLDL-cholesterol 
were analyzed 5.86 (6.42–5.31) months prior to surgery and 2.60 
(2.54–2.67), 6.50 (6.36–6.64), 12.04 (11.83–12.25), and 24.17 
(23.91–24.43) months after surgery. HbA1c were analyzed 4.38 
(3.87–4.89) months prior to surgery and 3.09 (3.04–3.14), 6.52 
(6.38–6.66), 12.81 (12.51–13.11), and 26.33 (25.47–27.19) months 
after surgery.
Patients in the two diabetic subgroups were older and had 
lower levels of total- and LDL-cholesterol, compared to the 
NDM subgroup (Table 1). The patient population as a whole 
was comparable to the reference group on many parameters 
apart from weight and BMI, but there were differences in 
lipid concentrations. Noticeably, the reference group HbA1c 
levels were significantly higher than those in the NDM patient 
group, indicating that there have been some individuals with 
undiagnosed diabetes in the reference group. Sphingomyelin 
levels were similar in patient- and reference population, but 
significantly lower for diabetic than non-diabetic patients 
before surgery (p <  4.3 e−8). Weight and BMI distribution, 
as well as postoperative weight loss and changes in BMI, 
were at all time points similar in all subgroups (Table S1 in 
Supplementary Material). As described previously, female 
and male patients were comparable before surgery as regard-
ing to age, weight, BMI, blood pressure, HbA1c, and plasma 
cholesterol (29). HbA1c concentrations, as shown in Table S1 
in Supplementary Material, decreased after surgery in all sub-
groups. Noteworthy, in the DMH-NDM group, mean HbA1c at 
all time points after surgery were within the normal range, not 
just below the diabetic threshold. In the DMH-DMH group, 
FigUre 1 | Serum sphingomyelin (SM) concentration (a) and its relation to body mass index (B) before and after RYGB surgery in non-diabetic and diabetic  
patient subgroups. NDM, patients without diabetes mellitus (DM); DMH-NDM, patients with DM in remission after RYGB; DMH-DMH, patients with DM not in 
remission after RYGB. Examples are from the female subpopulation. Male subpopulation showed similar trend, as seen in Table S2 in Supplementary Material.  
The curves for SM per kilogram bodyweight were similar to the ones per unit BMI shown in (B). p-Values from independent samples t-tests comparing patients  
with diabetes (DM) with patients without diabetes (NDM) at each time point are shown at the bottom of each figure. No statistical significance was found between 
the two diabetic subgroups. Longitudinal p-values from paired t-tests comparing postoperative SM at 3, 6, and 12 months after surgery with corresponding values 
before surgery are shown in columns to the right of the graph.
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mean HbA1c decreased to sub-diabetic, still hyperglycemic 
levels at 6 and 12 months after surgery, but returned to diabetic 
levels at 24 months. Mean sphingomyelin concentration in the 
whole group was 413.1 (400.7–425.5) μmol/L before surgery. 
There was a significant difference between genders, as the 
concentration was higher in female than in male patients, 
434.3 (419.8–448.9) μmol/L compared to 367.6 (347.8–387.4) 
μmol/L (p < 3.9 e−7). The gender difference was also clear in 
the reference population, females 460.8 (443.8–477.8) μmol/L 
and males 371.1 (351.1–391.1) μmol/L (p < 9.9 e−11).
Following RYGB, sphingomyelin mean concentration for the 
whole patient population was significantly reduced to 394.0 
(382.2–405.8) at 3  months after surgery (p  <  2.6 e−5), and 
stayed at the new level during follow-up (Figure  1A; Table S2 
in Supplementary Material). This decrease was explained by a 
decrease in the NDM group, whereas changes in sphingomyelin 
levels in the two diabetic subgroups were small and not statisti-
cally significant. During follow-up, the difference observed 
before surgery between diabetic and non-diabetic subgroups 
disappeared, for male pati ents this occurred already 6  months 
after surgery, while the difference for female patients was still 
significant at 12, but not at 24  months after surgery. Although 
not significantly different from 0, delta (Δ) sphingomyelin values 
showed a positive trend in the DMH-NDM subgroup (Figure 2A), 
with mean Δ-values significantly different from mean Δ-values 
in the NDM subgroup (p < 0.007). Also the percentage relative 
changes (Figure 2B), clearly shows that the significant decrease in 
sphingomyelin in the non-diabetic subgroup was not observed in 
the diabetic subgroups. The differences between patients with and 
without diabetes were independent of gender. There was no linear 
FigUre 2 | Changes in sphingomyelin (SM) concentration after Roux-en-y gastric bypass (RYGB) surgery in non-diabetic and diabetic subgroups. Figures show 
mean and a 95% confidence interval of the mean for differences (Δ SM) between SM concentrations before surgery and at 3 (squares), 6 (circles), 12 (triangles), and 
24 months (diamonds) after RYGB, respectively (a); and the relative change in SM at 3 months after surgery in percent (B). NDM, patients without diabetes mellitus 
(DM); DMH-NDM, patients with DM in remission after RYGB; DMH-DMH, patients with DM not in remission after RYGB. Shown p-values are from a one-sample 
t-test, comparing the change with 0. Significantly different values when compared to corresponding value in the NDM subgroup is marked with a * (p < 0.05).
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relationship between sphingomyelin and weight before surgery, 
and no association between change in sphingomyelin and weight 
loss. There was although a significant negative correlation between 
weight and sphingomyelin at 12 and 24  months after surgery 
[r(90) = −0.284, p <  0.006] and [r(24) = −0.414, p <  0.035], 
respectively. In all patients, weight at all time points after surgery 
correlated strongly and with high significance with weight before 
surgery. Also, post- and preoperative sphingomyelin concentra-
tions were strongly correlated.
Standardized to body weight or BMI, sphingomyelin concen-
tration rose significantly after RYGB per kilogram bodyweight 
(Figure 3) or unit BMI (Figure 1B; Table S2 in Supplementary 
Material) in all patient subgroups, irrespective of diabetes status. 
In percent, relative postoperative increase in sphingomyelin 
concentration per kilogram bodyweight was largest in the two 
diabetic subgroups (Table 2) and significant for male patients. In 
relation to cholesterol, the ratio between sphingomyelin and total 
cholesterol concentration in moles per liter increased from 0.088 
(0.086–0.090), before surgery, to 0.101 (0.099–0.103) 3 months 
after RYGB (p = 2.6 e−32). During the next 2 years of follow-up, 
the ratio gradually decreased to the same level as before surgery.
Lipid concentrations at all time points are shown in Table S1 
in Supplementary Material. Total cholesterol after RYGB was 
initially reduced followed by a slight increase during the rest of 
follow-up, probably due to the increase in HDL-cholesterol after 
6 months. All subgroups follow the same pattern of changes in 
total cholesterol and HDL-cholesterol. LDL-cholesterol showed 
a significant reduction at 3  months after surgery, but for the 
diabetic subgroups, the change was no longer significant after 
6  months. Triglycerides, was reduced in all subgroups after 
RYGB, with a continuous downward trend during follow-up. 
VLDL-cholesterol decreased significantly after RYGB in all 
subgroups and stayed low. Figures  4A–C show changes in 
cholesterol, triglyceride, and HDL-cholesterol concentrations 
standardized to bodyweight. For LDL- and VLDL-cholesterol 
standardized to bodyweight, changes after RYGB were smaller 
or less significant.
Sphingomyelin levels correlated positively with total-, HDL-, 
and LDL-cholesterol before and after surgery (Table S3 in 
Supplementary Material). The correlations were strongest 
bet ween sphingomyelin and total cholesterol [rs(218) = 0.801, p < 1.5 
e−50] as well as between sphingomyelin and LDL-cholesterol 
[rs(218) = 0.731, p < 4.9 e−38] at 3 months after surgery. Twelve 
months after surgery, the correlation between sphingomy-
elin and LDL-cholesterol was less strong than before surgery 
[rs(136) = 0.527, p < 3.0 e−11]. The correlation between sphingo-
myelin and HDL-cholesterol at 3 months after surgery was mod-
erate [rs(218) = 0.350, p < 1.1 e−7], but was stronger 12 months 
after surgery [rs(136) = 0.518, p < 7.8 e−11]. Sphingomyelin did not 
correlate with VLDL or triglycerides.
DiscUssiOn
Previous studies have reported a decreased serum or plasma 
sphingomyelin concentration after weight loss in humans (34, 
35). We could not confirm any linear relationship between sphin-
gomyelin and body weight in all our patients, except for weak 
correlations at 12 and 24  months after surgery, where a higher 
body weight was associated to a lower sphingomyelin concentra-
tion. We found a decrease in level of sphingomyelin after weight 
loss following RYGB in the non-diabetic subgroup, but not in the 
diabetic subgroups. Also, patients with diabetes had a significantly 
lower sphingomyelin concentration before surgery than patients 
without diabetes.
The source of serum sphingomyelin is not known. Dietary 
sphingomyelin does not seem to be a source of circulating 
sphingomyelin as it is slowly and incompletely digested by 
intestinal alkaline sphingomyelinase (alkSMase) and neutral 
ceramidase to sphingosine (36). Intact sphingolipids or ceramides 
are not absorbed, but sphingosine is to a large extent (11, 24, 36). 
Considering that alkSMase is active primarily in the jejunum and 
depends on bile in order to be active in the gut lumen (25), RYGB 
surgery bypassing duodenum and the pancreatic duct may entirely 
change the gut metabolism of sphingolipids. The increased load 
FigUre 3 | Sphingomyelin (SM) per kilogram bodyweight before and after 
Roux-en-Y gastric bypass (RYGB) surgery for female patients (a) and male 
patients (B). Figure show boxes with median, 25 and 75% centiles before 
surgery and at 3, 6, and 12 months after RYGB.
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of sphingomyelin to the distal intestine and colon may change its 
absorbance kinetics, of which we however have no information 
about. The liver seems to be the major source of serum lipids (37). 
Human liver contains higher concentrations of ceramides and 
saturated fatty acids than subcutaneous and visceral fat, but it is 
not known if this extends to high concentrations of sphingomy-
elin generated by sphingomyelin synthesis in the liver.
Sphingomyelin is together with cholesterol a major constituent 
of cellular membranes (17), influencing membrane fluidity (38), 
and the proportion of sphingomyelin in cellular membrane lipid 
rafts affect receptor signaling, likely by regulating receptor accu-
mulation and dimerization (39). By preventing insulin receptor 
dimerization, lipid raft alterations are suggested to play a role in 
development of insulin resistance (28), and DM may arise as a 
consequence of an unbalanced membrane sphingolipid composi-
tion (40). In addition, degradation of membrane sphingomyelin 
to ceramide increases ceramide concentration in lipid rafts, which 
in the pancreas promotes beta cell apoptosis (14). It is not clear, if 
sphingomyelin serum levels reflect the alterations in the plasma 
membrane seen in DM.
The levels of serum sphingomyelin were significantly higher 
in patients without diabetes compared to patients with diabetes 
before surgery, while no difference was seen between the two 
diabetic subgroups. For female patients, the difference between 
the diabetic subgroups on one side and the non-diabetic 
subgroup on the other still persisted at 12, but not 24 months 
after RYGB. For male patients, the difference was no longer 
significant at 3 months after RYGB. After RYGB, sphingomyelin 
levels only decreased in the patients without diabetes. This 
suggests that sphingomyelin is physiologically related to the 
metabolic state of the patients and that sphingomyelin reflects 
the glucose tolerance state. The causal relationship is, however, 
far from clear. Also, considering the specificity of our assay that 
measures total sphingomyelin, it is possible, that the constant 
sphingomyelin concentration in diabetic subgroups may cover 
over combined increases and decreases in individual sphingo-
myelin species.
Intriguingly, although absolute sphingomyelin levels were 
stationary after RYGB in diabetic subgroups, sphingomyelin 
levels per BMI unit or kg bodyweight differed marginally between 
patients with and without diabetes and increased almost in parallel 
for all patient subgroups, including the diabetic. This suggests that 
the changed anatomy after RYGB results in a general alteration 
of sphingolipid metabolism which is independent of diabetes. In 
contrast, serum levels of sphingomyelin seem to be indigenously 
related to the diabetic state. Differences between genders might 
be explained by differences in distribution of body mass and fluid 
compartments.
Sphingolipid metabolism is likely to have an important role 
in regulating intestinal absorption of other lipids, like choles-
terol (25). The strong correlations that we saw between serum 
sphingomyelin and plasma total- and LDL-cholesterol indicate 
that their metabolisms or ways of transport also are connected in 
serum/plasma. Sphingomyelin is known to be the most abundant 
sphingolipid in circulating LDL (16). Correlations between LDL-
cholesterol and sphingomyelin were strong before surgery and for 
a short time after, but diminished later after RYGB. This pattern 
was also seen for correlation to HDL-cholesterol, but in the reverse 
direction, which might be a reflection of an altered lipoprotein 
particle composition, including transfer of sphingolipids between 
LDL- and HDL-particles and their receptors. Total- and LDL-
cholesterol were significantly lower in the two diabetic subgroups 
compared to the patients without diabetes. The likely reason for 
this was a more frequent treatment with statins in patients with 
diabetes, as 59% of diabetic patients compared to only 9% of 
non-diabetic patients were prescribed cholesterol lowering drugs 
before surgery. After RYGB, LDL-cholesterol stayed lower in the 
group with persistent diabetes. This also was a likely effect of dif-
ferences in statin treatment between the subgroups. Statins do not 
to interfere with sphingomyelin synthesis (41).
FigUre 4 | Lipids per kilogram bodyweight before and after Roux-en-Y gastric bypass (RYGB) surgery. Figure show mean and a 95% confidence interval of the 
mean before surgery and at 3, 6, and 12 months after RYGB for the whole patient population for total cholesterol (a), triglycerides (B) and HDL-cholesterol (c).
TaBle 2 | Relative percentage increases in sphingomyelin concentration per kg bodyweight at 3, 6, and 12 months after RYGB surgery.
nDM DMh-nDM DMh-DMh p-Value
n Mean (95% ci) n Mean (95% ci) n Mean (95% ci)
Months after rYgB % % %
3 All 116 16.0 (13.0–19.1) 26 25.6 (15.2–36.1) 14 21.1 (9.3–32.9) 0.052
Females 89 17.5 (13.9–21.2) 16 21.5 (7.1–35.9) 5 8.5 (-1.1–31.7)a 0.398
Males 27 11.2 (6.2–16.1) 10 32.3 (15.3–49.2) 9 28.2 (12.3–44.0) 0.002
6 All 84 19.6 (15.8–23.4) 15 38.5 (16.8–60.2) 11 31.1 (15.9–46.3) 0.091
Females 64 21.9 (17.7–26.0) 12 36.3 (9.9–62.8) 5 26.3 (6.9–49.5)a 0.498
Males 20 12.5 (3.6–21.4) 3 47.2 (17.7–81.8)a 6 35.1 (7.5–75)a 0.016
12 All 66 29.0 (23.6–34.4) 10 44.0 (20.9–67.2) 11 41.4 (26.7–56.2) 0.068
Females 50 32.8 (26.8–38.9) 6 31.3 (4.1–58.5) 3 28.5 (24.3–32.7) 0.418
Males 16 17.1 (6.2–28.0) 4 63.2 (18.3–96.0)a 8 46.3 (26.0–66.6) 0.002
Data are shown in percent (%) as mean with a 95% CI, except in a, were CI where larger than minimum and maximum values, which are reported instead. NDM, patients without 
diabetes mellitus (DM); DMH-NDM, patients with DM in remission after RYGB; DMH-DMH, patients with DM not in remission after RYGB; n, number of patients; RYGB, Roux-en-Y 
gastric bypass.
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Patients in the two diabetic subgroups were 8–9 years older 
than patients in the non-diabetic group. As both elevated triglyc-
erides and increased insulin resistance are known symptoms of 
the metabolic syndrome associated with obesity (42), we believe 
that some of the differences between the older diabetic subgroups 
and younger non-diabetic subgroup are expressions for the 
natural steps in development of a metabolic syndrome. We saw 
remarkable changes in triglycerides after RYGB in all subgroups. 
Knowing that triglycerides are only one chemical reaction away 
from diacylglycerol (DAG), the source of glycerophospholipids, 
likely to contribute to metabolic disease (16, 43) and that DAG 
and sphingomyelin metabolisms are connected (43), it seems 
plausible, that mechanisms affected by RYGB improving glucose 
hemostasis are upstream to both DAG and triglycerides, perhaps 
regulators of sphingolipid synthesis.
Our aim was to examine which effect RYGB had on serum 
sphingomyelin concentration in a population where the patient 
acts as its own clinical control before and after surgery. An obvi-
ous problem with this is that several factors cannot be considered 
stationary in a patient that at the same time undergoes a large weight 
reduction. At the time for the first postoperative blood sample 
3 months after surgery, there had already been a substantial mean 
weight loss of 18% or 22 kg, which for a majority of patients was 
more than 50% of the total weight loss after RYGB. The weight 
loss makes it difficult to draw conclusions on whether the changes 
in sphingomyelin and other lipids are reflections of a change in 
metabolism after RYGB or merely products of changes in body 
mass. To address this to some point, we chose to look at lipid 
concentrations adjusted to body weight and BMI, or relative to 
total cholesterol.
A limitation is that some pre-surgery serum samples were 
drawn months prior to RYGB, where the ideal would have been 
on the morning of surgery. Some changes in sphingomyelin con-
centration could, therefore, in theory be occurring already pre-
surgically. There was, however, no significant difference between 
patients with or without diabetes in mean time between blood 
sampling and operation, so a pre-surgical explanation would not 
sufficiently cover the observed difference between these patient 
groups.
The fact that the absolute values of sphingomyelin did not 
change in patients with diabetes, regardless of normalization 
of HbA1c, corroborates the notion that the diabetes state per-
sists in all diabetic patients and that obesity and diabetes are 
separate, although intertwined conditions (29). Importantly, 
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the natural reference group is the group of patients with no 
diabetes prior to surgery, and any changes in variables after 
RYGB should be compared to this reference group after RYGB. 
This is the case for fasting blood sugar (29) and sphingomyelin 
levels. HbA1C, which is a pivotal diagnostic variable, might 
also be in need of adjustment when used in a RYGB-operated 
population, as we see that HbA1c levels decrease after surgery 
in all subgroups, but although HbA1c is normalized in one of 
the diabetic subgroups, the difference in HbA1c between these 
patients and the patients in the non-diabetic subgroup still 
persists after RYGB (p-values <7.8 e−5, <0.001, <3.3 e−4, <2.2 
e−4 at 3, 6, 12, and 24 months after surgery, respectively.) The 
gap is even bigger, of course to the patients in the group with 
persistently high HbA1c. These non-responders to RYGB can 
perhaps, as suggested by Rubino et al., come to be classified as 
one or several new subtypes of type 2 diabetes (44). In order 
not to overestimate diabetes remission rate after RYGB, we 
chose a relatively defensive definition of remission and a rough 
division in two main diabetic groups. If we were to use ADA’s 
full remission criteria (32), some of the patients in the group 
with persistent hyperglycemia might in fact be partial respond-
ers, underlining the heterogeneity of this group. Complete 
responders, on the other hand, make up the vast majority of 
patients in the group with normalized HbA1c levels, making 
this group more homogenous.
Most research in the field of sphingolipid metabolism has 
been conducted on non-human beings, particularly mice. 
Caution should be shown when conjecturing from mice to 
humans, as the composition of lipoprotein particles differ 
between the two (45) and this may have an implication on the 
effects of sphingolipids. In addition, we only have scarce knowl-
edge of the composition of sphingomyelin and of sphingolipids 
in general (46). Future studies on these issues including the 
genetic structure of the vast lipid metabolic and regulatory 
network are needed.
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